Treatment of [99mTc]Tc‐hydroxy‐diphosphonate ([99mTc]Tc‐HDP) extravasation using hyaluronidase

• Published in: Pharmacology research & perspectives Vol. 12; no. 4; pp. e1232 - n/a
• Main Authors: Doornhof, Kevin R., de Lussanet de la Sablonière, Quido, Koolen, Stijn L. W., Konijnenberg, Mark W.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.08.2024; Wiley
• Subjects: Bisphosphonates; bone scintigraphy; Brochures; Conflicts of interest; Dosimetry; Drug dosages; Ethics; extravasation; Extravasation of Diagnostic and Therapeutic Materials - diagnostic imaging; Humans; Hyaluronoglucosaminidase; Nuclear medicine; Organotechnetium Compounds - administration & dosage; Radiation; radiology [99mTc]Tc‐HDP; Radiopharmaceuticals - administration & dosage; Scintigraphy; Skin; Technetium Tc 99m Medronate - analogs & derivatives; extravasation; radiology [99mTc]Tc‐HDP; bone scintigraphy
• ISSN: 2052-1707; 2052-1707
• DOI: 10.1002/prp2.1232

Extravasation of 99mTc‐labeled radiopharmaceuticals is generally considered to require no specific intervention. In the presented case, the use of hyaluronidase could have minimized the adverse effects resulting from such an extravasation. Currently, no guidelines exist regarding the use of hyaluronidase after extravasation of [99mTc]Tc‐HDP. Considering the low risk of administering hyaluronidase, it should be considered to limit the risk of injury after extravasation of [99mTc]Tc‐HDP. The spreading of [99mTC]Tc‐HDP after extravasation can be facilitated through administration of hyaluronidase. This can significantly reduce the tissue absorbed dose, potentially reducing the severity of adverse reactions.